1 Stock With Growth Potential
This could be one of the best stocks to consider during this bear market run.
Click for ticker & full details
Andy Pasternak, insider at Horizon Therapeutics Public

Andy Pasternak Insider Information

Andy Pasternak joined Horizon in November 2019. Before joining Horizon, Pasternak led the health care practice in the Americas at Bain & Company Inc., a global management consulting firm. At Bain, he advised boards of directors, CEOs and leadership teams at biopharmaceutical and medical technology companies, as well as private investment funds. His experience spans growth strategy, M&A strategy and execution, organizational design, executive and board governance and performance improvement. Pasternak was also a member of Bain’s Mergers and Acquisition practice, where he served as a leading expert on biopharmaceutical transactions, including acquisitions, business development, licensing deals and divestitures.

Before joining Bain, Pasternak was a founding partner in the Health & Life Sciences practice at Oliver Wyman, a global management consultancy. He also worked in the corporate finance group of J.P. Morgan Securities.

Throughout his career, Pasternak has worked across a wide range of specialty therapeutic areas (including rare diseases) and functions, including commercial, operations and R&D.

Pasternak earned a Master of Business Administration from the University of Chicago and a Bachelor of Arts in economics from Northwestern University.

What is Andy Pasternak's net worth?

The estimated net worth of Andy Pasternak is at least $2.18 million as of July 29th, 2022. Mr. Pasternak owns 34,047 shares of Horizon Therapeutics Public stock worth more than $2,181,732 as of August 17th. This net worth evaluation does not reflect any other assets that Mr. Pasternak may own. Additionally, Mr. Pasternak receives an annual salary of $1,670,000.00 as EVP at Horizon Therapeutics Public. Learn More about Andy Pasternak's net worth.

How old is Andy Pasternak?

Mr. Pasternak is currently 51 years old. There are 7 older executives and no younger executives at Horizon Therapeutics Public. The oldest executive at Horizon Therapeutics Public is Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D., Exec. VP & Chief Medical Officer, who is 67 years old. Learn More on Andy Pasternak's age.

What is Andy Pasternak's salary?

As the EVP of Horizon Therapeutics Public Limited, Mr. Pasternak earned a total compensation package of $6,947,326.00 in 2021. Mr. Pasternak earned a salary of $692,372.00, stock awards of $5,272,731.00, non-equity compensation of $814,368.00, and other compensation of $167,855.00.There are 2 executives that earn more than Mr. Pasternak. The highest earning executive at Horizon Therapeutics Public is Mr. Timothy P. Walbert, Chairman, Pres & CEO, who commands a salary of $5,540,000.00 per year. Learn More on Andy Pasternak's salary.

How do I contact Andy Pasternak?

The corporate mailing address for Mr. Pasternak and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected] Learn More on Andy Pasternak's contact information.

Has Andy Pasternak been buying or selling shares of Horizon Therapeutics Public?

During the last ninety days, Andy Pasternak has sold $400,464.50 of Horizon Therapeutics Public stock. Most recently, Andy Pasternak sold 4,850 shares of the business's stock in a transaction on Friday, July 29th. The shares were sold at an average price of $82.57, for a transaction totalling $400,464.50. Following the completion of the sale, the executive vice president now directly owns 34,047 shares of the company's stock, valued at $2,811,260.79. Learn More on Andy Pasternak's trading history.

Who are Horizon Therapeutics Public's active insiders?

Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Are insiders buying or selling shares of Horizon Therapeutics Public?

During the last twelve months, Horizon Therapeutics Public insiders bought shares 1 times. They purchased a total of 745 shares worth more than $49,669.15. During the last twelve months, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 1,057,327 shares worth more than $110,655,224.55. The most recent insider tranaction occured on August, 4th when EVP Sean M Clayton bought 745 shares worth more than $49,669.15. Insiders at Horizon Therapeutics Public own 2.5 % of the company. Learn More about insider trades at Horizon Therapeutics Public.

Information on this page was last updated on 8/4/2022.

Andy Pasternak Insider Trading History at Horizon Therapeutics Public

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2022Sell4,850$82.57$400,464.5034,047View SEC Filing Icon  
6/10/2022Sell762$85.36$65,044.3238,897View SEC Filing Icon  
2/18/2022Sell1,313$94.82$124,498.66View SEC Filing Icon  
1/6/2022Sell7,987$99.57$795,265.59View SEC Filing Icon  
12/7/2021Sell1,525$100.00$152,500.00View SEC Filing Icon  
11/4/2021Sell30,168$113.04$3,410,190.72View SEC Filing Icon  
9/9/2021Sell23,250$107.84$2,507,280.0046,604View SEC Filing Icon  
See Full Table

Andy Pasternak Buying and Selling Activity at Horizon Therapeutics Public

This chart shows Andy Pasternak's buying and selling at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Read More

Today's Range

Now: $63.31
Low: $63.14
High: $64.04

50 Day Range

MA: $79.67
Low: $64.08
High: $90.61

2 Week Range

Now: $63.31
Low: $60.76
High: $120.54

Volume

14,573 shs

Average Volume

3,530,396 shs

Market Capitalization

$14.59 billion

P/E Ratio

19.54

Dividend Yield

N/A

Beta

1.12
1 Stock With Growth Potential
This could be one of the best stocks to consider during this bear market run.
Click for ticker & full details